Mukai Satomi 向井智美

Researcher Number	10706146
Other IDs
Affiliation (Current)	2025: 愛知県がんセンター(研究所), 分子腫瘍学分野, 研究員
Affiliation (based on the past Project Information) *help	2021 – 2025: 愛知県がんセンター(研究所), 分子腫瘍学分野, 研究員 2018 – 2019: 愛知県がんセンター(研究所), 分子腫瘍学分野, 研究員 2016 – 2017: 愛知県がんセンター(研究所), 分子腫瘍学部, 研究員 2015: 大阪大学, 微生物病研究所, 特任研究員(常勤)
Review Section/Research Field	Principal Investigator Basic Section 50010:Tumor biology-related / 0901:Oncology and related fields / General physiology / Tumor biology Except Principal Investigator Basic Section 50020:Tumor diagnostics and therapeutics-related
Keywords	Principal Investigator 悪性中皮腫 / Hippo pathway / O-GlcNAc / 核輸送 / ヌクレオポリン / O-GlcNAc 修飾 / Optogenetics / 核輸送動態 / CRISPR library / 合成致死 … More / NF2 / シグナル伝達 / 癌 / 共培養 / MET / Lats1 / ZEB1 / EMT / LATS1 … More Except Principal Investigator 悪性中皮腫 / 分子標的 / 癌遺伝子 / 転写 / シグナル伝達 / Hippoシグナル伝達系 / 分子標的治療 / 細胞増殖 / 遺伝子変異 / シグナル伝達系 / 分子標的薬 / 細胞株 Less

ヌクレオポリンの糖鎖修飾異常による核輸送の変調と腫瘍進展における役割の解明Principal Investigator
- Principal Investigator
  
  向井智美
- Project Period (FY)
  2025 – 2027
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50010:Tumor biology-related
- Research Institution
  Aichi Cancer Center Research Institute
Identification of novel therapeutic targets for mesothelioma based on elucidation of TEAD-independent functions of YAP/TAZ
- Principal Investigator
  
  関戸好孝
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Aichi Cancer Center Research Institute
ナノボディを用いた O-GlcNAc 修飾異常による悪性中皮腫進展機構の解明Principal Investigator
- Principal Investigator
  
  向井智美
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50010:Tumor biology-related
- Research Institution
  Aichi Cancer Center Research Institute
Exploring novel therapeutic targets for malignant mesothelioma using synthetic lethality.Principal Investigator
- Principal Investigator
  
  Mukai Satomi
- Project Period (FY)
  2021 – 2022
- Research Category
  
  Grant-in-Aid for Research Activity Start-up
- Review Section
  
  0901:Oncology and related fields
- Research Institution
  Aichi Cancer Center Research Institute
Development of a new therapeutic modality using YAP1/TAZ inhibitors against malignant mesothelioma
- Principal Investigator
  
  Sekido Yoshitaka
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Aichi Cancer Center Research Institute
Elucidation of progression mechanism of malignant pleural mesothelioma using co-culture systemsPrincipal Investigator
- Principal Investigator
  
  MUKAI Satomi
- Project Period (FY)
  2017 – 2018
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  General physiology
- Research Institution
  Aichi Cancer Center Research Institute
Elucidation of a novel EMT-MET control mechanism by LATS1 kinasePrincipal Investigator
- Principal Investigator
  
  Mukai Satomi
- Project Period (FY)
  2015 – 2016
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Tumor biology
- Research Institution
  Aichi Cancer Center Research Institute
  Osaka University

All 2023 2022 2021 2019 2018 2017 2016 2015

All Journal Article Presentation

[Journal Article] Damage and Cell Survival in Hippo Pathway Kinase LATS2-Inactivated Malignant Mesothelioma2022
- Author(s)
  Suzuki K,Tange M,Yamagishi R, Hanada H, Mukai S, Sato T, Tanaka T, Akashi T, Kadomatsu K, Maeda T, Miida T, Takeuchi T, Murakami H, Sekido Y, Murakami-Tonami Y
- Journal Title
  
  Cell Death Discovery
  
  Volume: 8 Issue: 1 Pages: 446-446
- DOI
  10.1038/s41420-022-01232-w
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K06863, KAKENHI-PROJECT-21K18251, KAKENHI-PROJECT-19K16809, KAKENHI-PROJECT-21K20854
[Journal Article] Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively2021
- Author(s)
  Sato Tatsuhiro、Nakanishi Hayao、Akao Ken、Okuda Maho、Mukai Satomi、Kiyono Tohru、Sekido Yoshitaka
- Journal Title
  
  Cancer Cell International
  
  Volume: 21 Issue: 1 Pages: 546-546
- DOI
  10.1186/s12935-021-02248-5
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19H03527, KAKENHI-PROJECT-19K22670
[Journal Article] Silencing of SmgGDS, a Novel mTORC1 Inducer That Binds to RHEBs, Inhibits Malignant Mesothelioma Cell Proliferation2021
- Author(s)
  Sato Tatsuhiro、Mukai Satomi、Ikeda Haruna、Mishiro-Sato Emi、Akao Ken、Kobayashi Toshiyuki、Hino Okio、Shimono Wataru、Shibagaki Yoshio、Hattori Seisuke、Sekido Yoshitaka
- Journal Title
  
  Molecular Cancer Research
  
  Volume: - Issue: 5 Pages: 921-931
- DOI
  10.1158/1541-7786.mcr-20-0637
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19H03527, KAKENHI-PROJECT-18K07255
[Journal Article] TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.2019
- Author(s)
  Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, Aoki M, Hasegawa Y, Sekido Y
- Journal Title
  
  Oncogene
  
  Volume: 38 Issue: 11 Pages: 1966-1978
- DOI
  10.1038/s41388-018-0417-7
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K19628, KAKENHI-PROJECT-18K15231, KAKENHI-PLANNED-26111005, KAKENHI-PROJECT-16H04706, KAKENHI-PROJECT-18H02686, KAKENHI-PROJECT-16K07139, KAKENHI-PROJECT-17K15569
[Journal Article] Withaferin A induces cell death selectively in androgen-independent prostate cancer cells but not in normal fibroblast cells.2015
- Author(s)
  Nishikawa Y, Okuzaki D, Fukushima, K, Mukai S, Ohno S, Ozaki Y, Yabuta N, Nojima H.
- Journal Title
  
  PLoS One
  
  Volume: 10 Issue: 7 Pages: e0134137-e0134137
- DOI
  10.1371/journal.pone.0134137
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26430112, KAKENHI-PROJECT-15K14407, KAKENHI-PROJECT-15K18408
[Journal Article] ELAS1-mediated inhibition of the cyclin G1-B'γ interaction promotes cancer cell apoptosis via stabilization and activation of p53.2015
- Author(s)
  Ohno S, Naito Y, Mukai S, Yabuta N, Nojima H
- Journal Title
  
  Oncogene
  
  Volume: 34 Issue: 49 Pages: 5983-5996
- DOI
  10.1038/onc.2015.47
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-26430112, KAKENHI-PROJECT-15K18408
[Journal Article] Phosphorylation of CHO1 by Lats1/2 regulates the centrosomal activation of LIMK1 during cytokinesis.2015
- Author(s)
  Ayumi Okamoto, Norikazu Yabuta, Satomi Mukai, Kosuke Torigata, Hiroshi Nojima
- Journal Title
  
  Cell Cycle
  
  Volume: Epub ahead of print Issue: 10 Pages: 0-0
- DOI
  10.1080/15384101.2015.1026489
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-13J05951, KAKENHI-PROJECT-15K18408
[Journal Article] Lats1 suppresses centrosome overduplication by modulating the stability of Cdc25B.2015
- Author(s)
  Mukai S, Yabuta N, Yoshida K, Okamoto A, Miura D, Furuta Y, Abe T, Nojima H.
- Journal Title
  
  Scientific Reports
  
  Volume: 5 Issue: 1 Pages: 16173-16173
- DOI
  10.1038/srep16173
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-26430112, KAKENHI-PROJECT-15K18408
[Presentation] ヌクレオポリンの O-GlcNAc 修飾異常を介した腫瘍進展メカニズムの解明2023
- Author(s)
  向井智美、佐藤龍洋、亀井保博、加藤輝、三城恵美、青木正博、藪田紀一、廣島健三、関戸好孝
- Organizer
  第46回日本分子生物学会年会
- Data Source
  KAKENHI-PROJECT-22K07182
[Presentation] Hippoシグナル系が破綻した中皮腫細胞は過剰なO-GlcNAc 修飾が引き起こされ、核輸送能の亢進による悪性化を引き起こす2023
- Author(s)
  向井智美、佐藤龍洋、三城恵美、青木正博、藪田紀一、廣島健三、関戸好孝
- Organizer
  第4回日本石綿・中皮腫学会学術集会
- Data Source
  KAKENHI-PROJECT-22K07182
[Presentation] ヌクレオポリンの翻訳後修飾異常に着目した、YAP/TAZ の活性化を伴うがんに対する新規治療の可能性2023
- Author(s)
  向井智美、佐藤龍洋、亀井保博、三城恵美、青木正博、藪田紀一、廣島健三、関戸好孝
- Organizer
  第96回日本生化学会大会
- Invited
- Data Source
  KAKENHI-PROJECT-22K07182
[Presentation] Therapeutic potential of targeting enhanced O-GlcNAcylation in malignant mesothelioma with disrupted Hippo pathway.2022
- Author(s)
  Satomi Mukai, Tatsuhiro Sato, Emi Mishiro-Sato, Masahiro Aoki, Norikazu Yabuta3, Yoshitaka Sekido
- Organizer
  第81回日本癌学会総会
- Data Source
  KAKENHI-PROJECT-22K07182
[Presentation] 悪性中皮腫におけるO-GlcNAc修飾異常を介した腫瘍進展メカニズムの解明2022
- Author(s)
  向井智美、佐藤龍洋、三城恵美、青木正博、藪田紀一、関戸好孝
- Organizer
  第45回日本分子生物学会年会
- Data Source
  KAKENHI-PROJECT-22K07182
[Presentation] 悪性中皮腫におけるO-GlcNAc修飾異常を介した腫瘍進展メカニズムの解明2021
- Author(s)
  向井智美、佐藤龍洋、三城恵美、青木正博、藪田紀一、関戸好孝
- Organizer
  第44回日本分子生物学会年会
- Data Source
  KAKENHI-PROJECT-19H03527
[Presentation] 悪性中皮腫細胞に対する新規TEAD阻害剤の効果の検討2021
- Author(s)
  赤尾謙、佐藤龍洋、向井智美、平野雅規、関戸好孝
- Organizer
  第2回日本石綿・中皮腫学会学術集会
- Data Source
  KAKENHI-PROJECT-19H03527
[Presentation] LATS2変異悪性中皮腫に対する新規合成致死遺伝子を標的とした抗腫瘍活性の包括的評価2021
- Author(s)
  鈴木浩也、向井智美、三井田孝、関戸好孝、村上（渡並）優子
- Organizer
  第25回日本がん分子標的治療学会学術集会
- Data Source
  KAKENHI-PROJECT-19H03527
[Presentation] O-GlcNAc修飾は悪性中皮腫の腫瘍進展を促進する2019
- Author(s)
  向井智美、佐藤龍洋、三城（佐藤）恵美、青木正博、藪田紀一、関戸好孝
- Organizer
  第78回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-19H03527
[Presentation] SmgGDSによるRheb-mTORC1シグナル伝達制御と悪性中皮種がん化への関与2019
- Author(s)
  佐藤龍洋、向井智美、関戸好孝
- Organizer
  第42回日本分子生物学会年会
- Data Source
  KAKENHI-PROJECT-19H03527
[Presentation] IL-1受容体拮抗薬はHippo経路の破綻した悪性中皮腫細胞の進展を抑制する2018
- Author(s)
  向井　智美, 松下　明弘, 佐藤　龍洋, 藤下　晃章, 青木　正博, 関戸　好孝
- Organizer
  第22回　日本がん分子標的治療学会学術集会
- Data Source
  KAKENHI-PROJECT-17K15569
[Presentation] LATS2 inhibits O-GlcNAcylation in malignant mesothelioma cells.2018
- Author(s)
  Satomi Mukai, Tatsuhiro Sato, Emi Mishiro-Sato, Masahiro Aoki, Norikazu Yabuta, Yoshitaka Sekido.
- Organizer
  第77回　日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-17K15569
[Presentation] 悪性中皮腫におけるHippo経路の破綻による腫瘍進展機構2018
- Author(s)
  向井　智美, 松下　明弘, 佐藤　龍洋, 藤下　晃章, 三城　恵美、奥田　真帆、青木　正博、関戸　好孝.
- Organizer
  第41回日本分子生物学会年会
- Invited
- Data Source
  KAKENHI-PROJECT-17K15569
[Presentation] Transcriptional coactivator TAZ induces malignant mesothelioma progression via enhancement of IL-1b transcription2017
- Author(s)
  Satomi Mukai, Akihiro Matsushita, Tatsuhiro Sato, Teruaki Fujishita, Masahiro Aoki, Yoshitaka Sekido
- Organizer
  第76回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-17K15569
[Presentation] Lats1 suppresses E-cadherin expression through phosphorylation of ZEB1 in invasive breast cancer2016
- Author(s)
  向井智美、藪田紀一、谷野美智枝、関戸好孝、田中伸哉、野島博
- Organizer
  第75回日本癌学会学術総会
- Place of Presentation
  パシフィコ横浜（横浜市）
- Year and Date
  2016-10-06
- Data Source
  KAKENHI-PROJECT-15K18408
[Presentation] Lats1とLats2によるZEB1のリン酸化は乳癌細胞においてEMT-METを制御する2015
- Author(s)
  向井智美、鳥形康輔、藪田紀一、野島博
- Organizer
  第74回日本癌学会学術総会
- Place of Presentation
  名古屋国際会議場
- Year and Date
  2015-10-08
- Data Source
  KAKENHI-PROJECT-15K18408
[Presentation] Lats1キナーゼはZEB1をリン酸化し、乳癌細胞におけるEMT-METを制御する2015
- Author(s)
  向井智美、安藤有美、加藤依香、鳥形康輔、藪田紀一、野島博
- Organizer
  第38回日本分子生物学会年会　第88回日本生化学会大会　合同大会
- Place of Presentation
  神戸ポートアイランド
- Year and Date
  2015-12-01
- Data Source
  KAKENHI-PROJECT-15K18408

1. Sekido Yoshitaka (00311712)

# of Collaborated Projects: 2 results

# of Collaborated Products: 8 results
2. 佐藤龍洋 (70547893)

# of Collaborated Projects: 2 results

# of Collaborated Products: 7 results
3. 薮田紀一

# of Collaborated Projects: 0 results

# of Collaborated Products: 3 results
4. 野島博

# of Collaborated Projects: 0 results

# of Collaborated Products: 3 results
5. 村上優子

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Mukai Satomi 向井 智美

Research Projects

Research Products

Co-Researchers

ヌクレオポリンの糖鎖修飾異常による核輸送の変調と腫瘍進展における役割の解明Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Identification of novel therapeutic targets for mesothelioma based on elucidation of TEAD-independent functions of YAP/TAZ

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

ナノボディを用いた O-GlcNAc 修飾異常による悪性中皮腫進展機構の解明Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Exploring novel therapeutic targets for malignant mesothelioma using synthetic lethality.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of a new therapeutic modality using YAP1/TAZ inhibitors against malignant mesothelioma

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Elucidation of progression mechanism of malignant pleural mesothelioma using co-culture systemsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Elucidation of a novel EMT-MET control mechanism by LATS1 kinasePrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Damage and Cell Survival in Hippo Pathway Kinase LATS2-Inactivated Malignant Mesothelioma2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Silencing of SmgGDS, a Novel mTORC1 Inducer That Binds to RHEBs, Inhibits Malignant Mesothelioma Cell Proliferation2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Withaferin A induces cell death selectively in androgen-independent prostate cancer cells but not in normal fibroblast cells.2015

Author(s)

Journal Title

DOI

Data Source

[Journal Article] ELAS1-mediated inhibition of the cyclin G1-B'γ interaction promotes cancer cell apoptosis via stabilization and activation of p53.2015

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Phosphorylation of CHO1 by Lats1/2 regulates the centrosomal activation of LIMK1 during cytokinesis.2015

Author(s)

Journal Title

DOI

Mukai Satomi 向井智美